Vanda’s antipsychotic candidate iloperidone rejected by FDA
The Carlat Psychiatry Report, Volume 6, Number 9, September 2008
https://www.thecarlatreport.com/newsletter-issue/tcprv6n9/
Issue Links: Learning Objectives | Editorial Information
Topics: Antipsychotics
Section editor, Glen Spielmans, PhD
The FDA issued a Not Approvable letter regarding Vanda Pharmaceutical’s antipsychotic medication iloperidone (Fanapta). The agency based its decision on iloperidone’s question able efficacy results versus risperidone.
You can't view details of this content, please login or buy subscription here
Section editor, Glen Spielmans, PhD
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.